查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2111208

分子診斷市場預測至2034年－全球產品、技術、分析物、測試類型、檢體類型、測試施行地點、應用、最終使用者和地區分析

Molecular Diagnostics Market Forecasts To 2034 - Global Analysis By Product (Reagents & Kits, Instruments and Software & Services), Technology, Analyte, Test Type, Sample Type, Testing Location, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球分子診斷市場規模將達到 216 億美元，並在預測期內以 10.8% 的複合年成長率成長，到 2034 年將達到 490 億美元。

分子診斷市場是一個快速成長的醫療領域，它利用創新的分子技術分析DNA、RNA、生物標記和其他生物指標來識別疾病。該市場涵蓋了PCR、定序平台和分子檢測等解決方案，應用於傳染病檢查、癌症診斷和個人化醫療等領域。在全球範圍內，由於人們越來越重視早期檢測、精準診斷和有效治療方案的選擇，對分子診斷工具的需求正在加速成長。不斷擴大的研究活動、不斷完善的醫療基礎設施以及精準醫療的普及，為市場參與企業創造了新的機會。這些技術能夠為多種疾病提供快速、高靈敏度和可靠的診斷訊息，從而改善臨床療效。

感染疾病的傳播

全球感染疾病病例的不斷增加，使得分子診斷解決方案的需求日益成長。這些技術能夠以高精度和高速度檢測病毒、細菌和其他病原體，使醫護人員能夠提供適當的治療並有效控制感染疾病疫情。近期公共衛生領域的挑戰凸顯了可靠的分子檢測系統在監測和控制疾病傳播方面的重要性。各國政府、醫療機構和診斷實驗室對先進檢測基礎設施的投資顯著增加。隨著對加強感染控制、改善監測計畫和快速識別病原體的需求不斷成長，分子診斷正成為全球醫療衛生體系和疾病預防策略的重要組成部分。

分子診斷技術高成本

由於分子診斷平台初始成本、維護成本和營運成本高昂，其昂貴的性能對市場成長構成重大挑戰。先進的檢測設備、耗材和專業檢查室所需的巨額投資，可能會阻礙小規模醫療機構和診斷中心採用這些技術。此外，員工培訓和設施維修等額外成本也會進一步影響其普及。新興市場有限的保險報銷機制和經濟因素也限制了這些技術的普及。儘管持續的技術創新正在降低檢測成本，但分子診斷解決方案所需的高額初始投資仍然是全球醫療機構廣泛採用這些技術的主要障礙。

新興市場分子診斷的擴張

在開發中國家，醫療衛生系統的持續改進和現代化為分子診斷的發展創造了極具吸引力的機會。醫療基礎設施的擴建、人們對先進檢測方法的認知度不斷提高以及對醫療技術投入的增加，都在推動這些地區分子診斷技術的普及。各國政府積極支持旨在提高疾病檢測準確性、發展檢查室和監測公共衛生的各項舉措，從而創造了對分子診斷平台的需求。不斷上漲的醫療成本和日益成長的患者群體進一步提升了市場的潛力。能夠提供價格合理、擴充性且高效的診斷解決方案的製造商，將擁有擴大市場佔有率的有利條件。對改善醫療服務可近性的日益重視，將繼續推動新興市場對分子診斷技術的採用。

監管方面的不確定性和不斷變化的合規要求

不斷變化的法規環境給從事分子診斷產品研發和商業化的公司帶來了挑戰。製造商必須遵守不斷變化的安全、性能檢驗、臨床證據和資料保護等方面的要求。各國核准標準的差異會使全球營運更加複雜，並增加行政負擔。新的監管要求可能需要在測試、文件編制和產品改進方面投入更多資金，從而導致成本增加和研發週期延長。對於小規模的市場參與企業，由於資金和技術資源有限，滿足這些要求尤其具有挑戰性。因此，監管的不確定性會影響創新步伐，增加商業風險，並影響分子診斷公司的整體成長潛力。

新型冠狀病毒（COVID-19）的影響：

新冠疫情催生了對快速可靠診斷方法的空前需求，顯著推動了分子診斷市場的成長和發展。基於PCR的分子檢測成為識別SARS-CoV-2感染、支持全球公共衛生工作的關鍵解決方案。疫情刺激了對檢查室基礎設施、診斷技術和醫學研究的投資。醫院和檢測中心加強了分子檢測能力，以支持篩檢、監測和感染控制工作。儘管目前對新冠病毒檢測的需求較尖峰時段有所下降，但疫情提高了人們對分子診斷的認知，並加速了其在全球感染疾病和其他醫療領域的應用。

在預測期內，「試劑和試劑盒」細分市場預計將佔據最大的市場佔有率。

預計在預測期內，「試劑和試劑盒」細分市場將佔據最大的市場佔有率。這是因為這些元件對於分子診斷工作流程的功能至關重要。它們廣泛應用於基於PCR的檢測、定序應用、基因分析和疾病檢測程序。對感染疾病、腫瘤疾病和遺傳性疾病的精準診斷需求不斷成長，推動了分子診斷試劑盒和試劑使用量的成長。它們的重複使用、檢測技術的持續創新以及在醫療保健領域的廣泛應用，都促進了該細分市場的成長。此外，臨床檢測數量的增加和研究應用的擴展預計將使分子診斷行業對試劑和試劑盒的需求保持強勁。

在預測期內，藥物基因體學領域預計將呈現最高的複合年成長率。

在預測期內，由於個人化醫療和標靶治療的日益普及，藥物基因體學學領域預計將呈現最高的成長率。分子診斷技術使醫療專業人員能夠分析影響個別藥物反應的基因變異，從而幫助最佳化治療方案選擇並改善患者預後。對精準醫療日益成長的需求、基因組學研究的進步以及基因檢測在臨床決策中日益廣泛的應用，正在加速藥物基因體學解決方案的普及。製藥公司也在藥物研發和臨床試驗中利用藥物藥物基因體學檢測來提高治療效果。預計這些因素將推動該領域在分子診斷市場中的快速擴張。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其完善的醫療保健生態系統、先進的診斷能力和強大的創新環境。基因組研究的大量投資、生物技術的進步以及現代化的實驗室基礎設施正在推動該地區分子診斷解決方案的廣泛應用。精準醫療、癌症篩檢、感染疾病診斷和早期檢測技術的日益普及，也刺激了對分子診斷技術的需求。完善的醫療保健體系、保險覆蓋範圍以及行業的積極參與，進一步促進了市場成長。此外，診斷服務供應商和醫療機構之間持續進行的研究舉措和策略合作，也進一步鞏固了北美在全球分子診斷產業的領先地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療保健投資的增加、診斷基礎設施的擴建以及先進檢測技術的廣泛應用。該地區對疾病早期檢測、感染疾病監測、腫瘤診斷和基因檢測解決方案的需求日益成長。醫療保健服務的可近性提高、精準醫療意識的增強以及政府的支持，正在推動分子診斷平台的應用。此外，龐大的患者群體、慢性病和感染疾病的日益普遍以及生物技術活動的活性化，也為亞太地區新興經濟體的市場擴張創造了巨大的機會。

免費客製化服務：

所有購買此報告的客戶均可從以下免費自訂選項中選擇一項：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球分子診斷市場：依產品分類

  • 試劑和試劑盒
  • 裝置
  • 軟體和服務

第6章 全球分子診斷市場：依技術分類

  • 聚合酵素鏈鎖反應（PCR）
  • 恒溫核酸增幅法（INAAT）
  • 次世代定序（NGS）
  • 桑格定序
  • 微陣列
  • 原位雜合反應（ISH）
  • 轉錄媒介增幅（TMA）
  • 利用CRISPR進行分子診斷

第7章 全球分子診斷市場：依分析物質分類

  • DNA
  • RNA
  • DNA和RNA

第8章 全球分子診斷市場：依檢測類型分類

  • 定性測試
  • 定量測試

第9章 全球分子診斷市場：依樣本類型分類

  • 血
  • 血漿和血清
  • 組織
  • 尿
  • 唾液
  • 鼻咽拭子和口咽拭子
  • 痰
  • 航班
  • 腦脊髓液（CSF）
  • 其他臨床檢體

第10章 全球分子診斷市場：依檢測施行地點

  • 中心檢查室的檢測
  • 即時偵測 (POC)
  • 家庭測試

第11章 全球分子診斷市場：依應用分類

  • 感染疾病診斷
  • 腫瘤學
  • 基因疾病檢測
  • 生殖健康檢查
  • 血液篩檢
  • 藥物基因體學
  • 神經病變
  • 心血管疾病
  • 呼吸系統疾病
  • 消化系統疾病
  • 內分泌和代謝疾病
  • 移植診斷
  • 其他臨床用途

第12章 全球分子診斷市場：依最終用戶分類

  • 醫院
  • 臨床實驗室
  • 參考實驗室
  • 診斷中心
  • 學術研究機構
  • 製藥和生物技術公司
  • 受託研究機構（CRO）
  • 公共衛生研究所
  • 血庫
  • 其他最終用戶

第13章 全球分子診斷市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第14章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第15章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第16章：公司簡介

  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • QIAGEN NV
  • Siemens Healthineers AG
  • Hologic, Inc.
  • Becton, Dickinson and Company（BD）
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Revvity, Inc.
  • bioMerieux SA
  • Sysmex Corporation
  • Seegene Inc.
  • Exact Sciences Corporation
  • Guardant Health, Inc.
  • DiaSorin SpA
Product Code: SMRC38864

According to Stratistics MRC, the Global Molecular Diagnostics Market is accounted for $21.6 billion in 2026 and is expected to reach $49.0 billion by 2034 growing at a CAGR of 10.8% during the forecast period. The Molecular Diagnostics Market represents a growing healthcare field that uses innovative molecular technologies to identify diseases by examining DNA, RNA, biomarkers, and other biological indicators. It covers solutions including PCR, sequencing-based platforms, and molecular assays applied in infectious disease testing, cancer diagnosis, and personalized healthcare approaches. Increasing focus on early detection, accurate diagnosis, and effective treatment selection is accelerating demand for molecular diagnostic tools globally. Expanding research activities, healthcare infrastructure improvements, and adoption of precision medicine are creating new opportunities for market participants. These technologies enhance clinical outcomes by providing rapid, sensitive, and dependable diagnostic information for diverse conditions.

Market Dynamics:

Driver:

Increasing Prevalence of Infectious Diseases

Increasing cases of infectious diseases worldwide are creating strong demand for molecular diagnostic solutions. These technologies help detect viruses, bacteria, and other pathogens with high precision and speed, allowing healthcare professionals to provide appropriate treatments and manage outbreaks effectively. Recent public health challenges have emphasized the importance of reliable molecular testing systems for monitoring and controlling disease spread. Investments by governments, healthcare institutions, and diagnostic laboratories in advanced testing infrastructure are increasing significantly. As the need for improved infection management, surveillance programs, and rapid pathogen identification grows, molecular diagnostics is becoming a critical component of global healthcare systems and disease prevention strategies.

Restraint:

High Cost of Molecular Diagnostic Technologies

Expensive molecular diagnostic platforms represent a significant challenge for market growth due to their high acquisition, maintenance, and operational expenses. Advanced testing equipment, consumables, and specialized laboratory requirements require substantial financial resources, which can restrict adoption among smaller healthcare providers and diagnostic centers. Additional costs related to workforce training and facility upgrades further impact implementation. Limited reimbursement policies and affordability concerns in emerging markets also reduce accessibility to these technologies. While ongoing innovations are helping decrease testing expenses, the considerable upfront investment needed for molecular diagnostic solutions remains a key factor slowing broader utilization across healthcare institutions worldwide.

Opportunity:

Expansion of Molecular Diagnostics in Emerging Markets

Developing economies present attractive opportunities for molecular diagnostics growth as healthcare systems continue to improve and modernize. Expanding medical infrastructure, increased awareness of advanced testing methods, and rising investments in healthcare technology are driving adoption in these regions. Governments are supporting initiatives focused on better disease detection, laboratory development, and public health monitoring, creating demand for molecular diagnostic platforms. Growing healthcare expenditures and larger patient populations further contribute to market potential. Manufacturers offering affordable, scalable, and efficient diagnostic solutions are well positioned to expand their presence. The increasing focus on improving healthcare accessibility will continue to support molecular diagnostics adoption across emerging markets.

Threat:

Regulatory Uncertainty and Changing Compliance Requirements

Evolving regulatory environments create obstacles for companies involved in molecular diagnostics development and commercialization. Manufacturers must comply with changing requirements related to safety, performance validation, clinical evidence, and data protection. Differences in approval standards across countries can complicate global expansion and increase administrative burdens. New regulatory expectations may require additional investments in testing, documentation, and product adjustments, leading to higher expenses and longer development timelines. Smaller market participants may find these requirements particularly challenging due to limited financial and technical resources. Regulatory uncertainty can therefore affect innovation speed, increase business risks, and influence the overall growth potential of molecular diagnostic companies.

Covid-19 Impact:

The COVID-19 outbreak had a major impact on the growth and development of the Molecular Diagnostics Market by creating unprecedented demand for fast and reliable diagnostic methods. PCR-based molecular testing became a primary solution for identifying SARS-CoV-2 infections and supporting global public health responses. The pandemic encouraged investments in laboratory infrastructure, diagnostic technologies, and healthcare research. Hospitals and testing centers increased their molecular testing capabilities to support screening, monitoring, and infection control efforts. While COVID-19 testing requirements have reduced compared with peak periods, the pandemic improved awareness of molecular diagnostics and accelerated their adoption for infectious diseases and other medical applications worldwide.

The Reagents & Kits segment is expected to be the largest during the forecast period

The Reagents & Kits segment is expected to account for the largest market share during the forecast period, because these components are fundamental to the functioning of molecular diagnostic workflows. They are widely used across PCR-based testing, sequencing applications, genetic analysis, and disease detection procedures. Rising demand for accurate diagnosis of infectious diseases, oncology conditions, and inherited disorders is increasing the utilization of molecular diagnostic kits and reagents. Their recurring consumption, continuous innovation in assay technologies, and broad applicability across healthcare settings contribute to segment growth. Additionally, increasing clinical testing volumes and expanding research applications are expected to maintain strong demand for reagents and kits in the molecular diagnostics industry.

The Pharmacogenomics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Pharmacogenomics segment is predicted to witness the highest growth rate, due to the increasing adoption of personalized medicine and targeted therapies. Molecular diagnostic technologies are enabling healthcare providers to analyze genetic variations that influence individual responses to medications, helping optimize treatment selection and improve patient outcomes. Growing demand for precision healthcare, advancements in genomic research, and increased integration of genetic testing into clinical decision-making are accelerating the adoption of pharmacogenomics solutions. Pharmaceutical companies are also utilizing pharmacogenomic testing during drug development and clinical trials to enhance therapeutic effectiveness. These factors are expected to drive rapid expansion of this segment within the molecular diagnostics market.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by its well-developed healthcare ecosystem, advanced diagnostic capabilities, and strong innovation environment. The region experiences high adoption of molecular testing solutions due to significant investments in genomic research, biotechnology advancements, and modern laboratory infrastructure. Increasing utilization of precision medicine, cancer testing, infectious disease diagnostics, and early detection methods is driving demand for molecular diagnostic technologies. Supportive healthcare frameworks, reimbursement availability, and strong industry participation further enhance market growth. Moreover, ongoing research initiatives and strategic collaborations among diagnostic providers and healthcare institutions continue to reinforce North America's dominance in the global molecular diagnostics industry.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to increasing healthcare investments, expanding diagnostic infrastructure, and rising adoption of advanced testing technologies. The region is experiencing growing demand for early disease detection, infectious disease monitoring, oncology diagnostics, and genetic testing solutions. Improving healthcare access, increasing awareness of precision medicine, and supportive government initiatives are encouraging the adoption of molecular diagnostic platforms. Additionally, the presence of a large patient population, rising prevalence of chronic and infectious diseases, and growing biotechnology activities are creating significant opportunities for market expansion across emerging economies in the Asia-Pacific region.

Key players in the market

Some of the key players in Molecular Diagnostics Market include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Bio-Rad Laboratories, Inc., QIAGEN N.V., Siemens Healthineers AG, Hologic, Inc., Becton, Dickinson and Company (BD), Illumina, Inc., Agilent Technologies, Inc., Revvity, Inc., bioMerieux SA, Sysmex Corporation, Seegene Inc., Exact Sciences Corporation, Guardant Health, Inc. and DiaSorin S.p.A.

Key Developments:

In May 2026, QIAGEN partnered with Inpeco to advance automated molecular diagnostic workflows for QuantiFERON latent tuberculosis (TB) testing.

In January 2026, hermo Fisher Scientific announced a strategic collaboration with NVIDIA to combine AI technologies with laboratory instruments, software, and workflows.

Products Covered:

  • Reagents & Kits
  • Instruments
  • Software & Services

Technologies Covered:

  • Polymerase Chain Reaction (PCR)
  • Isothermal Nucleic Acid Amplification (INAAT)
  • Next-Generation Sequencing (NGS)
  • Sanger Sequencing
  • Microarrays
  • In Situ Hybridization (ISH)
  • Transcription-Mediated Amplification (TMA)
  • CRISPR-Based Molecular Diagnostics

Analyses Covered:

  • DNA
  • RNA
  • DNA & RNA

Test Types Covered:

  • Qualitative Tests
  • Quantitative Tests

Sample Types Covered:

  • Blood
  • Plasma & Serum
  • Tissue
  • Urine
  • Saliva
  • Nasopharyngeal & Oropharyngeal Swabs
  • Sputum
  • Stool
  • Cerebrospinal Fluid (CSF)
  • Other Clinical Specimens

Testing Locations Covered:

  • Central Laboratory Testing
  • Point-of-Care (POC) Testing
  • Home-Based Testing

Applications Covered:

  • Infectious Disease Diagnostics
  • Oncology
  • Genetic Disease Testing
  • Reproductive Health Testing
  • Blood Screening
  • Pharmacogenomics
  • Neurological Disorders
  • Cardiovascular Diseases
  • Respiratory Diseases
  • Gastrointestinal Diseases
  • Endocrine & Metabolic Disorders
  • Transplant Diagnostics
  • Other Clinical Applications

End Users Covered:

  • Hospitals
  • Clinical Laboratories
  • Reference Laboratories
  • Diagnostic Centers
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Public Health Laboratories
  • Blood Banks
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Molecular Diagnostics Market, By Product

  • 5.1 Reagents & Kits
  • 5.2 Instruments
  • 5.3 Software & Services

6 Global Molecular Diagnostics Market, By Technology

  • 6.1 Polymerase Chain Reaction (PCR)
  • 6.2 Isothermal Nucleic Acid Amplification (INAAT)
  • 6.3 Next-Generation Sequencing (NGS)
  • 6.4 Sanger Sequencing
  • 6.5 Microarrays
  • 6.6 In Situ Hybridization (ISH)
  • 6.7 Transcription-Mediated Amplification (TMA)
  • 6.8 CRISPR-Based Molecular Diagnostics

7 Global Molecular Diagnostics Market, By Analyte

  • 7.1 DNA
  • 7.2 RNA
  • 7.3 DNA & RNA

8 Global Molecular Diagnostics Market, By Test Type

  • 8.1 Qualitative Tests
  • 8.2 Quantitative Tests

9 Global Molecular Diagnostics Market, By Sample Type

  • 9.1 Blood
  • 9.2 Plasma & Serum
  • 9.3 Tissue
  • 9.4 Urine
  • 9.5 Saliva
  • 9.6 Nasopharyngeal & Oropharyngeal Swabs
  • 9.7 Sputum
  • 9.8 Stool
  • 9.9 Cerebrospinal Fluid (CSF)
  • 9.10 Other Clinical Specimens

10 Global Molecular Diagnostics Market, By Testing Location

  • 10.1 Central Laboratory Testing
  • 10.2 Point-of-Care (POC) Testing
  • 10.3 Home-Based Testing

11 Global Molecular Diagnostics Market, By Application

  • 11.1 Infectious Disease Diagnostics
  • 11.2 Oncology
  • 11.3 Genetic Disease Testing
  • 11.4 Reproductive Health Testing
  • 11.5 Blood Screening
  • 11.6 Pharmacogenomics
  • 11.7 Neurological Disorders
  • 11.8 Cardiovascular Diseases
  • 11.9 Respiratory Diseases
  • 11.10 Gastrointestinal Diseases
  • 11.11 Endocrine & Metabolic Disorders
  • 11.12 Transplant Diagnostics
  • 11.13 Other Clinical Applications

12 Global Molecular Diagnostics Market, By End User

  • 12.1 Hospitals
  • 12.2 Clinical Laboratories
  • 12.3 Reference Laboratories
  • 12.4 Diagnostic Centers
  • 12.5 Academic & Research Institutes
  • 12.6 Pharmaceutical & Biotechnology Companies
  • 12.7 Contract Research Organizations (CROs)
  • 12.8 Public Health Laboratories
  • 12.9 Blood Banks
  • 12.10 Other End Users

13 Global Molecular Diagnostics Market, By Geography

  • 13.1 North America
    • 13.1.1 United States
    • 13.1.2 Canada
    • 13.1.3 Mexico
  • 13.2 Europe
    • 13.2.1 United Kingdom
    • 13.2.2 Germany
    • 13.2.3 France
    • 13.2.4 Italy
    • 13.2.5 Spain
    • 13.2.6 Netherlands
    • 13.2.7 Belgium
    • 13.2.8 Sweden
    • 13.2.9 Switzerland
    • 13.2.10 Poland
    • 13.2.11 Rest of Europe
  • 13.3 Asia Pacific
    • 13.3.1 China
    • 13.3.2 Japan
    • 13.3.3 India
    • 13.3.4 South Korea
    • 13.3.5 Australia
    • 13.3.6 Indonesia
    • 13.3.7 Thailand
    • 13.3.8 Malaysia
    • 13.3.9 Singapore
    • 13.3.10 Vietnam
    • 13.3.11 Rest of Asia Pacific
  • 13.4 South America
    • 13.4.1 Brazil
    • 13.4.2 Argentina
    • 13.4.3 Colombia
    • 13.4.4 Chile
    • 13.4.5 Peru
    • 13.4.6 Rest of South America
  • 13.5 Rest of the World (RoW)
    • 13.5.1 Middle East
      • 13.5.1.1 Saudi Arabia
      • 13.5.1.2 United Arab Emirates
      • 13.5.1.3 Qatar
      • 13.5.1.4 Israel
      • 13.5.1.5 Rest of Middle East
    • 13.5.2 Africa
      • 13.5.2.1 South Africa
      • 13.5.2.2 Egypt
      • 13.5.2.3 Morocco
      • 13.5.2.4 Rest of Africa

14 Strategic Market Intelligence

  • 14.1 Industry Value Network and Supply Chain Assessment
  • 14.2 White-Space and Opportunity Mapping
  • 14.3 Product Evolution and Market Life Cycle Analysis
  • 14.4 Channel, Distributor, and Go-to-Market Assessment

15 Industry Developments and Strategic Initiatives

  • 15.1 Mergers and Acquisitions
  • 15.2 Partnerships, Alliances, and Joint Ventures
  • 15.3 New Product Launches and Certifications
  • 15.4 Capacity Expansion and Investments
  • 15.5 Other Strategic Initiatives

16 Company Profiles

  • 16.1 F. Hoffmann-La Roche Ltd.
  • 16.2 Thermo Fisher Scientific Inc.
  • 16.3 Abbott Laboratories
  • 16.4 Danaher Corporation
  • 16.5 Bio-Rad Laboratories, Inc.
  • 16.6 QIAGEN N.V.
  • 16.7 Siemens Healthineers AG
  • 16.8 Hologic, Inc.
  • 16.9 Becton, Dickinson and Company (BD)
  • 16.10 Illumina, Inc.
  • 16.11 Agilent Technologies, Inc.
  • 16.12 Revvity, Inc.
  • 16.13 bioMerieux SA
  • 16.14 Sysmex Corporation
  • 16.15 Seegene Inc.
  • 16.16 Exact Sciences Corporation
  • 16.17 Guardant Health, Inc.
  • 16.18 DiaSorin S.p.A.

List of Tables

  • Table 1 Global Molecular Diagnostics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Molecular Diagnostics Market Outlook, By Product (2023-2034) ($MN)
  • Table 3 Global Molecular Diagnostics Market Outlook, By Reagents & Kits (2023-2034) ($MN)
  • Table 4 Global Molecular Diagnostics Market Outlook, By Instruments (2023-2034) ($MN)
  • Table 5 Global Molecular Diagnostics Market Outlook, By Software & Services (2023-2034) ($MN)
  • Table 6 Global Molecular Diagnostics Market Outlook, By Technology (2023-2034) ($MN)
  • Table 7 Global Molecular Diagnostics Market Outlook, By Polymerase Chain Reaction (PCR) (2023-2034) ($MN)
  • Table 8 Global Molecular Diagnostics Market Outlook, By Isothermal Nucleic Acid Amplification (INAAT) (2023-2034) ($MN)
  • Table 9 Global Molecular Diagnostics Market Outlook, By Next-Generation Sequencing (NGS) (2023-2034) ($MN)
  • Table 10 Global Molecular Diagnostics Market Outlook, By Sanger Sequencing (2023-2034) ($MN)
  • Table 11 Global Molecular Diagnostics Market Outlook, By Microarrays (2023-2034) ($MN)
  • Table 12 Global Molecular Diagnostics Market Outlook, By In Situ Hybridization (ISH) (2023-2034) ($MN)
  • Table 13 Global Molecular Diagnostics Market Outlook, By Transcription-Mediated Amplification (TMA) (2023-2034) ($MN)
  • Table 14 Global Molecular Diagnostics Market Outlook, By CRISPR-Based Molecular Diagnostics (2023-2034) ($MN)
  • Table 15 Global Molecular Diagnostics Market Outlook, By Analyte (2023-2034) ($MN)
  • Table 16 Global Molecular Diagnostics Market Outlook, By DNA (2023-2034) ($MN)
  • Table 17 Global Molecular Diagnostics Market Outlook, By RNA (2023-2034) ($MN)
  • Table 18 Global Molecular Diagnostics Market Outlook, By DNA & RNA (2023-2034) ($MN)
  • Table 19 Global Molecular Diagnostics Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 20 Global Molecular Diagnostics Market Outlook, By Qualitative Tests (2023-2034) ($MN)
  • Table 21 Global Molecular Diagnostics Market Outlook, By Quantitative Tests (2023-2034) ($MN)
  • Table 22 Global Molecular Diagnostics Market Outlook, By Sample Type (2023-2034) ($MN)
  • Table 23 Global Molecular Diagnostics Market Outlook, By Blood (2023-2034) ($MN)
  • Table 24 Global Molecular Diagnostics Market Outlook, By Plasma & Serum (2023-2034) ($MN)
  • Table 25 Global Molecular Diagnostics Market Outlook, By Tissue (2023-2034) ($MN)
  • Table 26 Global Molecular Diagnostics Market Outlook, By Urine (2023-2034) ($MN)
  • Table 27 Global Molecular Diagnostics Market Outlook, By Saliva (2023-2034) ($MN)
  • Table 28 Global Molecular Diagnostics Market Outlook, By Nasopharyngeal & Oropharyngeal Swabs (2023-2034) ($MN)
  • Table 29 Global Molecular Diagnostics Market Outlook, By Sputum (2023-2034) ($MN)
  • Table 30 Global Molecular Diagnostics Market Outlook, By Stool (2023-2034) ($MN)
  • Table 31 Global Molecular Diagnostics Market Outlook, By Cerebrospinal Fluid (CSF) (2023-2034) ($MN)
  • Table 32 Global Molecular Diagnostics Market Outlook, By Other Clinical Specimens (2023-2034) ($MN)
  • Table 33 Global Molecular Diagnostics Market Outlook, By Testing Location (2023-2034) ($MN)
  • Table 34 Global Molecular Diagnostics Market Outlook, By Central Laboratory Testing (2023-2034) ($MN)
  • Table 35 Global Molecular Diagnostics Market Outlook, By Point-of-Care (POC) Testing (2023-2034) ($MN)
  • Table 36 Global Molecular Diagnostics Market Outlook, By Home-Based Testing (2023-2034) ($MN)
  • Table 37 Global Molecular Diagnostics Market Outlook, By Application (2023-2034) ($MN)
  • Table 38 Global Molecular Diagnostics Market Outlook, By Infectious Disease Diagnostics (2023-2034) ($MN)
  • Table 39 Global Molecular Diagnostics Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 40 Global Molecular Diagnostics Market Outlook, By Genetic Disease Testing (2023-2034) ($MN)
  • Table 41 Global Molecular Diagnostics Market Outlook, By Reproductive Health Testing (2023-2034) ($MN)
  • Table 42 Global Molecular Diagnostics Market Outlook, By Blood Screening (2023-2034) ($MN)
  • Table 43 Global Molecular Diagnostics Market Outlook, By Pharmacogenomics (2023-2034) ($MN)
  • Table 44 Global Molecular Diagnostics Market Outlook, By Neurological Disorders (2023-2034) ($MN)
  • Table 45 Global Molecular Diagnostics Market Outlook, By Cardiovascular Diseases (2023-2034) ($MN)
  • Table 46 Global Molecular Diagnostics Market Outlook, By Respiratory Diseases (2023-2034) ($MN)
  • Table 47 Global Molecular Diagnostics Market Outlook, By Gastrointestinal Diseases (2023-2034) ($MN)
  • Table 48 Global Molecular Diagnostics Market Outlook, By Endocrine & Metabolic Disorders (2023-2034) ($MN)
  • Table 49 Global Molecular Diagnostics Market Outlook, By Transplant Diagnostics (2023-2034) ($MN)
  • Table 50 Global Molecular Diagnostics Market Outlook, By Other Clinical Applications (2023-2034) ($MN)
  • Table 51 Global Molecular Diagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 52 Global Molecular Diagnostics Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 53 Global Molecular Diagnostics Market Outlook, By Clinical Laboratories (2023-2034) ($MN)
  • Table 54 Global Molecular Diagnostics Market Outlook, By Reference Laboratories (2023-2034) ($MN)
  • Table 55 Global Molecular Diagnostics Market Outlook, By Diagnostic Centers (2023-2034) ($MN)
  • Table 56 Global Molecular Diagnostics Market Outlook, By Academic & Research Institutes (2023-2034) ($MN)
  • Table 57 Global Molecular Diagnostics Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 58 Global Molecular Diagnostics Market Outlook, By Contract Research Organizations (CROs) (2023-2034) ($MN)
  • Table 59 Global Molecular Diagnostics Market Outlook, By Public Health Laboratories (2023-2034) ($MN)
  • Table 60 Global Molecular Diagnostics Market Outlook, By Blood Banks (2023-2034) ($MN)
  • Table 61 Global Molecular Diagnostics Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.